Peter Farquhar is a journalist at Stockhead. With a career spanning from traditional print to digital media since 2007, he specializes in tech, business, and news, with a keen focus on markets, real estate, and notable figures like Elon Musk. He has been featured in Cigalah Group and Stockhead.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Australia (National)
Not enough data
Peter Farquhar appears to focus on stock market and investment topics within the context of the Australian Securities Exchange (ASX). His coverage includes seasonal aspects related to stocks, as well as event-driven content.
To effectively pitch to Peter, consider offering insights into specific ASX-listed companies or small-cap stocks. Additionally, providing expert analysis on trends in the Australian stock market would likely be well-received by him.
Given his focus on business and industry themes with a scientific element, pitches should align with these areas. It's important to note that Peter's geographic focus is national (Australia), so any pitches should bear this in mind.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Peter Farquhar
Barely a day has gone by without a fresh takeover offer for an ASX-listed company, with suitors targeting both large and small stocks across numerous sectors.
Good morning. On Stock head today, Guy Le Page summons the ghost of Elvis , a tempting junior uranium sandwich , and who's our momentum trader of the week, we hear you say?
It doesn't get much more compelling than “one of the most compelling base metal plays listed on ASX… and TSX-V for that matter.”
Barry FitzGerald Enough about uranium stocks. We get it. Besides, this month's commodity du jour is copper – finally.
Stockhead's Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data.
By: Peter Farquhar
By entering phase III, Opthea is in a rare pantheon of ASX-listed biotechs that includes Dimerix, Mesoblast and Paradigm.
Good morning, today on Stockhead, Nadine chats to Jessica Amir about how moomoo is making it easier to invest on the Nasdaq . Eliza Owen tells us
By: Peter Farquhar
Having served as Proteomics chief since he co-founded the company in 2001, Dr Richard Lipscombe is used to setbacks and delays.
(833) 317-6278 
